Functionalized peptides as antiviral agents
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
1. A compound represented by Formula (VI-6a),
or a pharmaceutically acceptable salt thereof, wherein
X is —CN; and
A is optionally substituted C 1 -C 8 alkyl or optionally substituted heteroaryl.
2. The compound of claim 1 wherein A is optionally substituted C 1 -C 8 alkyl.
3. The compound of claim 1 wherein A is optionally substituted heteroaryl.
4. The compound of claim 1 wherein A is selected from the group consisting of
each of which is optionally substituted.
5. The compound of claim 1 which is represented by Formula (X-e),
or a pharmaceutically acceptable salt thereof, wherein A and X are as defined in claim 1 .
6. The compound of claim 5 wherein A is selected from the group consisting of
7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
8. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .
9. The compound of claim 5 wherein A is optionally substituted C 1 -C 8 alkyl.
10. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 .